IMRX
Immuneering CorpKey Statistics
About Immuneering Corp
Immuneering Corp (IMRX) is an innovative biotechnology company at the forefront of developing advanced therapeutics for cancer and other serious diseases through its proprietary drug discovery platforms. Utilizing cutting-edge bioinformatics and machine learning technologies, Immuneering specializes in identifying and fine-tuning drug candidates that effectively target pivotal biological pathways, aimed at delivering therapies that improve patient outcomes while minimizing toxicity. With a strong pipeline of candidates and strategic partnerships, the company is strategically positioned to lead in the dynamic field of personalized medicine and targeted cancer therapies, offering significant growth potential for investors.
Fundamentals
| Revenue (TTM) | 455 |
| Gross Profit (TTM) | 158,830 |
| EBITDA | $-59.02M |
| Operating Margin | 0.00% |
| Return on Equity | -43.10% |
| Return on Assets | -26.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.38 |
| Price-to-Book | 1.55 |
| Price-to-Sales (TTM) | 563.62 |
| EV/Revenue | 191913.54 |
| EV/EBITDA | -1.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $64.70M |
| Float | $49.41M |
| % Insiders | 17.81% |
| % Institutions | 50.73% |
Historical Volatility
Volatility is currently expanding